BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for October:

Oct. 1-5
Obesity Society annual meeting.

Oct. 3
Onyx Pharmaceuticals ( ONXX) v. Bayer flurosorafenib litigation gets underway.

Oct. 5
Research abstracts for the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting made available.

Oct. 6
"Cancer Immunotherapy: A Long-Awaited Reality" conference, sponsored by MD Becker Partners.

Oct. 11-15
American Society for Human Genetics (ASHG) meeting.

Oct. 13
Rigel Pharmaceuticals ( RIGL) investor/analyst meeting: Asthma strategy and pipeline.

Oct. 19-21
ECTRIMS annual meeting. Key data presentations include Teva's ( TEVA) laquinimod and Biogen Idec's ( BIIB) BG-12.

Oct. 20-23
Infectious Disease Society of America (IDSA) meeting. Dynavax Technologies ( DVAX) Heplisav Hepatitis B data to be presented.

Oct 22-25
American Academy of Opthalmology (AAO) meeting.

Oct. 24
Amgen ( AMGN) third-quarter earnings.

Oct. 28
FDA approval decision for Pacira Pharmaceuticals' ( PCRX) Exparel for post-surgical pain management.
FDA approval decision date for Bristol-Myers Squibb ( BMY) and AstraZeneca's ( AZN) dapagliflozin for diabetes. An FDA advisory panel on July 19 voted to recommend against approval.

Biotech events expected before the end of September:
Biogen Idec: Top-line results of a phase III study of the multiple sclerosis drug BG-12 compared against Teva's Copaxone.
Exelixis ( EXEL): Top-line results of phase III study of cabozantinib in medullary thyroid cancer.

Sources: TheStreet research, company announcements, BioMedTracker

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback